BS
SLXP

Bow Street’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Bow Street’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-112,979
Closed -$13M – 40
2014
Q4 		$13M Buy
+112,979
New +$13.7M 4.6% 9

Other funds holding SLXP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bow Street's SLXP Position: Q1 2015 in Review

Bow Street sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 112,979 shares — an estimated $13M sold.

Bow Street first reported a position in SLXP in Q4 2014 and held it in 1 quarter. The position peaked at $13M in Q4 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

  • Bow Street reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
  • Bow Street sold 112,979 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $13M.
  • Bow Street first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q4 2014 and held it in 1 quarter.
  • Bow Street's SALIX PHARMACEUTICALS LTD DEL position peaked at $13M in Q4 2014.
  • 298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on Bow Street's 13F filing for Q1 2015, filed 14 May 2015.